BOARD OF DIRECTORS

Our Board of Directors comprises nine Directors, including four executive Directors, two non-executive Directors and three independent non-executive Directors. Our Directors serve a term of three years and may be re-elected for successive reappointments.

The following table sets out information in respect of the Directors.

Name	Age	Position/Title	Date of Appointment	Time of Joining our Group	Role and Responsibility
Executive Directors					
Dr. Jin Huajun (金華君)	[46]	Executive Director	January 7, 2020	August 1, 2019	Overall management of R&D and operation of our Group
		Chairman of the Board	January 20, 2020		
Dr. Huang Chen (黃晨)	[44]	Executive Director	February 8, 2021	September 1, 2019	Overseeing the early-stage R&D projects and intellectual property-related matters
Ms. He Zhou (何周)	[35]	Executive Director	December 1, 2025	August 3, 2020	Overseeing the operation of process and manufacturing matters of the Group
Ms. Tang Mengmeng (湯萌萌)	[39]	Executive Director	December 1, 2025	December 14, 2020	Registration and compliance related matters of the Group
Non-executive Directors					
Mr. Wang Yanan (王亞楠)	[32]	Non-executive Director	November 26, 2021	November 26, 2021	Providing professional advice, opinion and guidance to the Board
Dr. Zang Xiaojie (臧筱潔)	[35]	Non-executive Director	December 1, 2025	December 1, 2025	Providing professional advice, opinion and guidance to the Board
Independent Non-executive Directors					
Dr. Gao Zhengliang (高正良)	[51]	Independent Non-executive Director	March 19, 2026 (effective from the [REDACTED])	[REDACTED]	Offering independent advice to our Board on the operations and management of our Group
Dr. Hui Kai Lung (許佳龍)	[53]	Independent Non-executive Director	March 19, 2026 (effective from the [REDACTED])	[REDACTED]	Offering independent advice to our Board on the operations and management of our Group
Ms. Xiao Ying (肖瑩)	[49]	Independent Non-executive Director	December 1, 2025 (effective from the [REDACTED])	[REDACTED]	Offering independent advice to our Board on the operations and management of our Group

Note:

(1) There is no relationship among each Director and member of senior management of the Company.

Executive Directors

Dr. Jin Huajun (金華君), aged [46], our Founder and has been a Director and our Chairman of the Board since January 2020 and chief executive officer and chief technology officer of our Company since August 2020. He was re-designated as our executive Director on December 1, 2025. He is responsible for the overall management of R&D and operation of our Group.

Dr. Jin has extensive work experience in the life sciences field. He worked as an assistant researcher, primarily responsible for technical experiments, at South China Agricultural University (華南農業大學) from July 2006 to June 2007, Zhejiang Sci-Tech University (浙江理工大學) from July 2007 to December 2008 and South China University of Technology (華南理工大學) from January 2009 to May 2011. Each of these universities is principally engaged in higher education and scientific research. From January 2009 to November 2017, Dr. Jin also worked as a deputy director at the Gene Virus Treatment Laboratory of the Eastern Hepatobiliary Surgery Hospital, Naval Medical University (海軍醫學大學東方肝膽外科醫院基因病毒治療實驗室), a research centre principally engaged in medical services. From March 2014 to November 2017, he worked as a deputy director at the Tumour Biotherapy Diagnosis and Treatment Centre of the Second Military Medical University (第二軍醫大學腫瘤生物治療診治中心), a treatment centre principally engaged in higher education, where he was primarily responsible for technology research and development. From October 2013 to July 2019, Dr. Jin served as the chief technology officer and vice president at Shanghai Cell Therapy Group Co., Ltd. (上海細胞治療集團有限公司), ("**Shanghai Cell Therapy**")[(1)], where he was primarily responsible for research and development, product registration applications and clinical matters. Shanghai Cell Therapy is an Independent Third Party and has no business or financial relationship with the Company.

Since September 2022, he has served as the Executive Director of the Shanghai Biomedicine Committee of the China Democratic National Construction Association (中國民主建國會上海市生物醫藥委員會執行主任), appointed by the China Democratic National Construction Association Shanghai Committee (中國民主建國會上海市委員會). In October 2022, he was selected as one of the Outstanding Technical Leaders in Shanghai (上海市優秀技術帶頭人) by the Shanghai Science and Technology Commission (上海市科學技術委員會). In December 2023, he was recognized as a National Special Subsidy Expert (國家特殊津貼專家) by the State Council of the People's Republic of China (中華人民共和國國務院). In June 2024, he was appointed as a member of the Clinical Oncology Drug Research Professional Committee of the China Pharmaceutical Education Association (中國醫藥教育協會臨床腫瘤藥物研究專業委員會委員). In December 2024, Dr. Jin was selected as a Leading Talent under the Shanghai Oriental Talent Programme (上海東方人才計劃領軍人才) by the Shanghai Municipal Administration of Talent Work (上海市人才工作局). In April 2025, Dr. Jin was appointed as a member of the Cell and Gene Therapy Product Regulatory Research Professional Committee of the China Association for Pharmaceutical Supervision and Administration Research (中國藥品管理監督研究會細胞與基因治療產品監管研究專業委員會).

Dr. Jin received his bachelor's degree of science in life science from Wuhan University (武漢大學) in the PRC in June 2001. He received his doctorate degree of science in genetics from the same university in June 2006. In December 2018, he was conferred the senior professional title (正高級研究員職稱) by the Shanghai Municipal Human Resources and Social Security Bureau (上海市人力資源和社會保障局).

Dr. Huang Chen (黃晨), aged [44], was appointed as a Director of our Company since February 2021. Dr. Huang was appointed as our director of early-stage R&D and director of intellectual property in September 2019 and re-designated as deputy general manager on October 28, 2025. He was re-designated as our executive Director on December 1, 2025. Dr. Huang is responsible for overseeing the early-stage R&D projects and intellectual property-related matters.

Prior to joining our Group, Dr. Huang worked as intellectual property director at Shanghai Cell Therapy Group Co., Ltd. (上海細胞治療集團有限公司) from October 2017 to August 2019 primarily responsible for intellectual property planning and other related work in support of product

(1) Shanghai Cell Therapy is a company established in 2013 and primarily engaged in technology development, technical services, technical consultancy and technology transfer in the fields of cell therapy technology, biotechnology, and laboratory equipment technology, as well as tissue and cell storage services and cell preparation services.

research and development. From June 2017 to September 2017, Dr. Huang worked as a technology transformation specialist at Kunming Institute of Zoology of the Chinese Academy of Science (中科院昆明動物研究所), a institute principally engaged in biodiversity evolution, conservation and utilization research, where he was primarily responsible for the transformation of research institute technology into local application. From April 2016 to June 2017, Dr. Huang worked as a project manager at Shanghai Shengzhihua Intellectual Property Service Co., Ltd. (上海盛知華知識產權服務有限公司), a company principally engaged in intellectual property matters, where he was primarily responsible for technology assessment, market analysis, and analysis of technology-related patents. Dr. Huang worked as a patent attorney at Shanghai Beshining Law Office (上海弼興律師事務所), a law firm principally engaged in intellectual property cases, where he was primarily responsible for patent agency related services from December 2014 to April 2016.

Dr. Huang received his bachelor's degree of science in life science from Wuhan University (武漢大學) in the PRC in June 2004. He received his doctorate degree of science in biochemistry and molecular biology from the same university in June 2011.

Ms. He Zhou (何周), aged [35], was appointed as an executive Director of our Company on December 1, 2025. Ms. He was appointed as our director of process development department from August 2020 to August 2023 and senior director of process development center in August 2023, and re-designated as deputy general manager on October 28, 2025. Ms. He is responsible for overseeing the operation of process and manufacturing matters of the Group.

Prior to joining our Group, Ms. He worked as a senior researcher of process development at JW Therapeutics (Shanghai) Co., Ltd. (上海藥明巨諾生物科技有限公司), a company principally engaged in cellular immunotherapy, where he was primarily responsible for CAR-T cell products development from August 2018 to August 2020. From August 2015 to August 2018, Ms. He worked as a researcher at Shanghai Cell Therapy Research Institute (上海細胞治療研究院), where he was primarily responsible for the early-stage research and development of products such as CAR-T cells and TIL cells.

Ms. He obtained her bachelor's degree of science in biological science from Zhejiang Chinese Medical University (浙江中醫藥大學) in the PRC in June 2012. She obtained her master's degree of science in cell biology from Zhejiang University (浙江大學) in the PRC in March 2015.

Ms. Tang Mengmeng (湯萌萌), aged [39], was appointed as an executive Director of our Company on December 1, 2025, and the deputy general manager on October 28, 2025. Ms. Tang joined our Group in December 2020, primarily responsible for registration and compliance related matters of the Company and has been serving as our senior director of registration and compliance center since February 2024. She is responsible for registration and compliance related matters of the Group.

Prior to joining our Group, Ms. Tang worked at as senior R&D officer and project management officer Shanghai Cell Therapy Group Co., Ltd. (上海細胞治療集團有限公司) from November 2018 to November 2020 primarily responsible for research and development project management, project applications and related coordination matters. From January 2018 to October 2018, she worked as a salesperson at Shanghai Feiling Biotechnology Co., Ltd. (上海飛翎生物股份有限公司), a company principally engaged in biomedicine, where she was primarily responsible for sales matters. From February 2014 to November 2017, she worked as a process developer at Nuoyi Biopharmaceutical Co., Ltd. (諾一生物醫藥股份有限公司), a company principally engaged in process and drug registration, where she was primarily responsible for process development and drug registration. From November 2012 to November 2013, she worked as a R&D personnel at Shanghai Humantech Biotechnology Co. Ltd. (上海惠盾生物技術股份有限公司), a company principally engaged in therapeutic DC-CIK therapy for tumors, where she was primarily responsible for process development and clinical translation.

Ms. Tang obtained her bachelor's degree of science in biochemistry from Nanjing University (南京大學) in the PRC in June 2008. She further obtained her master's degree of science in biochemistry from Indiana University Bloomington in the United States in July 2012.

Non-executive Directors

Mr. Wang Yanan (王亞楠), aged [32], was appointed as a Director of our Company on November 26, 2021, and re-designated as our non-executive Director on September 26, 2025.

Mr. Wang has been serving as a rotating CEO, managing director, executive director, vice president and investment manager at Hangzhou Kaitai Investment Management Co., Ltd. (杭州凱泰資本管理有限公司) since June 2020, a company principally engaged in investments, where he was primarily responsible for project investment.

Mr. Wang obtained his bachelor's degree in pharmacy from Wuhan University (武漢大學) in the PRC in June 2015. He further obtained his master's degree in pharmacology from Shanghai Institute of Materia Medica, Chinese Academy of Sciences (中國科學院上海藥物研究所) in the PRC in June 2019.

Dr. Zang Xiaojie (臧筱潔), aged [35], was appointed as a non-executive Director of our Company since December 1, 2025.

She has over seven years of experience in healthcare venture capital and biotechnology investment, with a focus on innovative drug discovery and biopharmaceutic histotechnologies. Dr. Zang serves as a director at Eccogene Inc. (誠益生物開曼有限公司) since September 2022, a company principally engaged in biotechnology, where she was primarily responsible for providing guidance and advice on corporate strategy and governance. Since January 2021, she successively served as senior investment manager and investment director at Oriza Seed Fund Management Co. Ltd. (蘇州工業園區元禾原點創業投資管理有限公司), a company principally engaged in investment management, where she was primarily responsible for investment due diligence, portfolio management and other investment-related work for early-stage biotechnology companies. Dr. Zang served as a supervisor at Suzhou Tennor Therapeutics Co., Ltd. (蘇州丹諾醫藥股份有限公司), a company principally engaged in innovative biotechnology, where she was primarily responsible for supervising major matters, providing quality feedback and recommendations from June 2020 to January 2023 and Phoeno Thera Biopharmaceuticals Technology (Hangzhou) Co., Ltd. (輝諾生物醫藥科技(杭州)有限公司), a company principally engaged in new anti-infective drug development, where she was primarily responsible for supervising major matters, providing quality feedback and recommendations from December 2018 to September 2021.

Dr. Zang obtained her bachelor's degree in pharmacy in June 2013 from China Pharmaceutical University (中國藥科大學) in PRC. She further obtained her PhD degree in pharmacology in June 2018 from the same university.

Independent Non-executive Directors

Dr. Gao Zhengliang (高正良), aged [51], is an independent non-executive Director of our Group. Dr. Gao was appointed as an independent non-executive Director in March 2026, with effect from the [**REDACTED**]. Dr. Gao is primarily responsible for offering independent advice to our Board on the operations and management of our Group.

Dr. Gao has been a researcher at Shanghai University (上海大學), where he is primarily responsible for cell therapy and organoid research since June 2021 and the deputy director of the science popularization committee of Chinese Society for Cell Biology (中國細胞生物學學會), where he is primarily responsible for supporting and communicating science popularization work since December 2023. From July 2012 to June 2021, Dr. Gao served as a professor at Tongji University (同濟大學) and was primarily responsible for cell therapy, organoid research and management. From August 2006 to June 2012, Dr. Gao served as a postdoctoral researcher in molecular biology at the University of Texas Southwestern Medical Center.

Dr. Gao obtained his bachelor's degree in virology from Wuhan University (武漢大學) in the PRC in July 1996. He further obtained his master's degree in immunology from Chinese Center for Disease Control and Prevention (中國疾控中心病毒學研究所) in the PRC in August 1999. Dr. Gao obtained his PhD degree in cell biology from University of Massachusetts in the United States in September 2006.

Dr. Hui Kai Lung (許佳龍), aged [53], is an independent non-executive Director of our Group. Dr. Hui was appointed as an independent non-executive Director in March 2026, with effect from the [**REDACTED**]. Dr. Hui is primarily responsible for offering independent advice to our Board on the operations and management of our Group.

Dr. Hui has over 25 years of experience in teaching and research. Dr. Hui has been a professor at the Hong Kong University of Science and Technology since September 2008 and is primarily responsible for teaching, research and administrative work. From September 2006 to August 2008, Dr. Hui worked as an associate professor at City University of Hong Kong, primarily responsible for teaching and research. From August 2000 to May 2008, he served as an assistant professor at National University of Singapore, primarily responsible for teaching and research.

Dr. Hui obtained his bachelor's degree in information systems management from the Hong Kong University of Science and Technology in Hong Kong in June 1996. He further obtained his PhD degree in information management from the same university in June 2000.

Ms. Xiao Ying (肖瑩), aged [49], is an independent non-executive Director of our Group. Ms. Xiao was appointed as an independent non-executive Director in December 2025, with effect from the [**REDACTED**]. Ms. Xiao is primarily responsible for offering independent advice to our Board on the operations and management of our Group.

Ms. Xiao is a fund-appointed representative in Jiaxing Songhong Equity Investment Co., Ltd. (嘉興淞泓股權投資有限公司) since September 2021, a company principally engaged in investment projects and provide relevant services, where she is primarily responsible for equity investment. From February 2021 to August 2021, Ms. Xiao served as the deputy chief executive officer in Shanghai Jiangpin Enterprise Consulting Management Co., Ltd. (上海將聘企業諮詢管理有限公司), a company principally engaged in consulting, where she was primarily responsible for consulting and management matters. From June 2020 to February 2021, Ms. Xiao served as the executive vice president of the film park of Shanghai Film Group Film and Television Media Co., Ltd. (上海電影集團有限公司影視樂園), a company principally engaged in film and television shooting and production, where she was primarily responsible for the overall management of the company. From August 2017 to May 2020, Ms. Xiao worked as the financial controller in Shanghai Leapstack Technology Co., Ltd. (上海棧略數據技術有限公司), a company principally engaged in health insurance risk control, where she was primarily responsible for financial management. Ms. Xiao worked as an accounting manager in Konica Minolta Consulting Shanghai Company (柯尼卡美能達諮詢上海公司) from March 2006 to July 2017, a company principally engaged in providing office intelligence services, where she was primarily responsible for accounting matters. From March 2003 to October 2005, Ms. Xiao worked as an accounting supervisor at Walmart (China) Investment Co., Ltd. (沃爾瑪(中國)投資有限公司), a company principally engaged in retail industry, where she was primarily responsible for accounting matters. From June 2000 to March 2003, Ms. Xiao worked as an analyst at Jutian Securities Company Shanghai (巨田證券有限責任公司), a company principally engaged in investment management, where she was primarily responsible for investment consulting.

Ms. Xiao is currently an independent director of and the chairman of the audit committee of Shanghai Emperor Cleaning Hi-Tech Co., LTD. (上海洗霸科技股份有限公司) ("**Emperor Cleaning**"), a company listed on the Shanghai Stock Exchange (Stock Code: 603200), since September 2021. As the chairman of the audit committee of Emperor Cleaning, the primary duties of Ms. Xiao include, among others, (i) reviewing the company's financial information and its disclosure, (ii) supervising and evaluating the company's internal controls, (iii) examining the company's finances, (iv) supervising and evaluating the work of external audit institutions, and (v) supervising and evaluating internal audit work. Ms. Xiao was an independent non-executive director of Zoje Resources Investment Co., Ltd. (中捷資源投資股份有限公司), a company listed on the Shenzhen Stock Exchange (Stock Code: 002021) from September 2019 to December 2019, where she was primarily responsible for providing independent advice to the board of Zoje Resources Investment Co., Ltd. She was an independent non-executive director of Winfopay Network Technology (Shanghai) Co., Ltd. (上海捷鑫網絡科技股份有限公司), a company previously listed on the National Equities Exchange And Quotations and delisted on March 4, 2021 (Previous Stock Code: 839597) from August 2020 to February 2021, where she was primarily responsible for providing independent advice to the board of Winfopay Network Technology (Shanghai) Co., Ltd.

Ms. Xiao received her bachelor's degree of economics from Shanghai University of Finance and Economics (上海財經大學) in the PRC in June 1998. She received her master's degree in management from the same university in September 2005. Ms. Xiao was qualified as a senior accountant by Shanghai Municipal Finance Bureau in December 2010 and an auditor in October 2006 by the National Audit Office of the PRC.

SENIOR MANAGEMENT

The following table sets out information regarding the members of senior management of our Company.

Name	Age	Position/Title	Date of Appointment	Time of Joining our Group	Role and Responsibility
Dr. Jin Huajun (金華君)	[46]	Chief Executive Officer	August 1, 2020	August 1, 2019	Overall management of R&D and operation of our Group
		Chief Technology Officer	August 1, 2020		
Dr. Huang Chen (黃晨)	[44]	Deputy General Manager	October 28, 2025	September 1, 2019	Overseeing the early-stage R&D projects and intellectual property-related matters
Ms. He Zhou (何周)	[35]	Deputy General Manager	October 28, 2025	August 3, 2020	Overseeing the operation of process and manufacturing matters of the Group
Ms. Tang Mengmeng (湯萌萌)	[39]	Deputy General Manager	October 28, 2025	December 14, 2020	Registration and compliance related matters of the Group
Mr. Lin Shuwei (林樹偉)	[46]	Deputy General Manager	September 26, 2025	February 10, 2023	Clinical development and commercialization of the Group
Mr. Xiao Jinming (肖進明)	[39]	Deputy General Manager	October 28, 2025	September 18, 2025	Overall management of finance, investments and capital market activities of our Group
		Head of Financial Center	September 18, 2025		

Dr. Jin Huajun (金華君), aged [46], is our Founder and the chairman of the Board, executive Director, chief executive officer and chief technology officer of our Company. He is responsible for the overall management of R&D and operation of our Group. For details of his biography, see "— Board of Directors" above in this section.

Dr. Huang Chen (黃晨), aged [44], is an executive Director, and deputy general manager. Dr. Huang is responsible for overseeing the early-stage R&D projects and intellectual property-related matters. For details of his biography, see "— Board of Directors" above in this section.

Ms. He Zhou (何周), aged [35], is an executive Director and deputy general manager of our Company. Ms. He is responsible for overseeing the operation of process and manufacturing matters of the Group. For details of her biography, see "— Board of Directors" above in this section.

Ms. Tang Mengmeng (湯萌萌), aged [39], is an executive Director and deputy general manager of our Company. Ms. Tang is responsible for registration and compliance related matters of the Group. For details of her biography, see "— Board of Directors" above in this section.

Mr. Lin Shuwei (林樹偉), aged [46], is the deputy general manager of our Company. He joined the Company as a vice president, primarily responsible for clinical trial and commercialization of the Company and was re-designated as our deputy general manager on September 26, 2025. He is primarily responsible for the clinical development and commercialization of the Group.

Prior to joining our Group, Mr. Lin worked as a manager at Fosun Kite Biotechnology Co., Ltd. (復星凱特生物科技有限公司) a company principally engaged in CAR-T drug research, development, production and sales, where he was primarily responsible for CAR-T sales and nationwide brand management from August 2019 to January 2023. From October 2018 to August 2019, he worked as a manager at Innovent Biologics, Inc. (信達生物製藥), a company principally engaged in innovative drug research and development, production and sales, where he was primarily responsible for the brand management of oncology drugs. From April 2018 to October 2018, he worked as a manager at Bristol Myers Squibb (百時美施貴寶), a company principally engaged in prescription drug research and development, production and sales, where he was primarily responsible for the brand management of oncology drugs. From April 2010 to March 2018, he worked as a manager at Bayer HealthCare Limited (拜耳醫藥保健股份有限公司), a company principally engaged in prescription drug research and development, production and sales, where he was primarily responsible for the brand management of oncology drugs. From February 2007 to April 2010, he was employed as a staff at Xian Janssen Pharmaceutical Ltd. (西安楊森製藥有限公司), a company principally engaged in prescription drug research and development, production and sales, where he was primarily responsible for medical information communication. From July 2004 to August 2005, he worked as a staff at Deyi Medical Supplies (Shanghai) Co., Ltd. (德壹醫療用品(上海)有限公司), a company principally engaged in trade in biological products, where he was primarily responsible for research and development.

Mr. Lin received his bachelor's degree of science in biological science from Wuhan University (武漢大學) in the PRC in June 2004. He received his master's degree of business administration in Nanyang Technological University in Singapore in July 2017.

Mr. Xiao Jinming (肖進明), aged [39], is a deputy general manager of our Company. Mr. Xiao has also been serving as the head of Financial Center since September 2025, and appointed as the deputy general manager on October 28, 2025. He is responsible for the overall management of finance, investments and capital market activities of our Group.

Prior to joining our Group, Mr. Xiao served as investment banking business management committee vice president at China Securities Co., Ltd. (中信建投証券股份有限公司), a company listed on the Hong Kong Stock Exchange (Stock Code: 6066) and the Shanghai Stock Exchange (Stock Code: 601066), mainly responsible for investment banking business quality control and internal review committee from June 2021 to September 2025. From September 2016 to May 2021, he served as a business director at quality control department at Shanghai Securities Underwriting and Sponsorship Branch of Sinolink Securities Co., Ltd. (國金證券股份有限公司), a company listed on the Shanghai Stock Exchange (Stock Code: 600109), mainly responsible for investment banking business quality control and internal review. From April 2014 to September 2016, he worked as an assistant manager at the Shanghai Stock Exchange, mainly responsible for accounting supervision. He worked as an officer at Longyan Tobacco Industrial Co., Ltd. (龍岩煙草工業有限責任公司), a company principally engaged in research, development, production and sales of flue-cured cigarettes, where he was primarily responsible for accounting.

Mr. Xiao obtained his bachelor's degree in management from Xi'an Jiaotong University (西安交通大學) in the PRC in July 2009, and further obtained his master's degree in management from Xiamen University (廈門大學) in the PRC in June 2011. In addition, Mr. Xiao is a non-practicing CPA certified by The Chinese Institute of Certified Public Accountants in March 2021.

CONFIRMATION FROM OUR DIRECTORS

Rule 8.10 of the Listing Rules

Save as disclosed in the section headed "Relationship with Our Single Largest Group of Shareholders" in this Document, each of our Directors confirms that as of the Latest Practicable Date, he or she did not have any interest in a business which competes or is likely to compete, either directly or indirectly, with our Company's business which would require disclosure under Rule 8.10 of the Listing Rules.

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules in November 2025 and March 2026, and (ii) understands his or her obligations as a director of a [**REDACTED**] issuer under the Listing Rules.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors has confirmed (i) his/her independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules, (ii) he/she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company under the Listing Rules as of the Latest Practicable Date, and (iii) that there are no other factors that may affect his/her independence at the time of his/her appointments.

GENERAL

Save as disclosed above, none of the Directors or members of senior management of our Company has been a director of any public company the securities of which are listed on any securities market in Hong Kong or overseas in the three years immediately preceding the date of this Document.

None of the Directors or members of the senior management of our Company is related to any other Directors and members of the senior management of our Company.

JOINT COMPANY SECRETARIES

Ms. Zhao Jingjing (趙晶晶) was appointed as the Joint Company Secretary in October 2025. Prior to joining our Group, she worked in the legal compliance system of SAIC Anji Logistics Co., Ltd., City Development Law Firm (上海建緯律師事務所), and Securities Legal Department of Shanghai MindMotion Microelectronics Co., Ltd. (上海靈動微電子股份有限公司). Ms. Zhao obtained the Legal Professional Qualification Certificate issued by the Ministry of Justice of China in March 2014 and the Board Secretary Qualification Certificate of the Shanghai Stock Exchange in November 2023. Ms. Zhao obtained her master's degree in civil and commercial law in Shanghai University of Finance and Economics (上海財經大學) in the PRC in June 2014.

Ms. Yip Pui Tsang (葉珮琤) was appointed as a joint company secretary in October 2025. She has been qualified as a practicing lawyer in PRC and registered as a foreign lawyer with The Law Society of Hong Kong since 2015. She currently practices as a registered foreign lawyer at AllBright Law Offices (Hong Kong) LLP, bringing over ten years of professional experience in the corporate services field. Ms. Yip is also a Fellow of the Hong Kong Chartered Governance Institute and the Chartered Governance Institute in the United Kingdom. She obtained her Master of Business Administration degree from Anglia Ruskin University in the United Kingdom in June 2022.

BOARD COMMITTEES

Our Board delegates certain responsibilities to various committees. In accordance with the relevant PRC laws and regulations and the Corporate Governance Code, our Company has formed four Board committees, namely the Strategy Committee, the Audit Committee, the Remuneration and Appraisal Committee and the Nomination Committee.

Strategy Committee

We have established a Strategy Committee in order to monitor the strategy and business plans of the Company. The Strategy Committee consists of three Directors, namely Dr. Jin Hua Jun, Dr. Gao Zhengliang and Dr. Hui Kai Lung. Dr. Jin Huajun serves as the chairperson of the Strategy Committee. The primary duties of the Strategy Committee include, but not limited, to the following:

- to study and make recommendations on the long-term development and strategic planning of the Company;
- to study and make recommendations on major investment and financing schemes which require the approval of the Board as required by the Articles;
- to study and make recommendations on major capital operations and asset management projects which require the approval of the Board as required by the Articles;
- to study and make recommendations on other major issues affecting the development of the Company;
- to inspect the implementation of the above matters; and
- to deal with other matters authorized by the Board.

Audit Committee

We have established an Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraph D.3 of Part 2 of the Corporate Governance Code. The Audit Committee consists of three Directors, namely Ms. Xiao Ying, Dr. Hui Kai Lung and Dr. Gao Zhengliang. Ms. Xiao Ying, who holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules, serves as the chairperson of the Audit Committee. The primary duties of the Audit Committee include, but not limited to, the following:

- overseeing and evaluating the work of the external auditors, proposing the appointment, reappointment, change and removal of the external auditors to our Board, approving the remuneration and terms of engagement of the external auditors, addressing issues relating to the resignation or dismissal of external auditor, and reviewing and monitoring the external auditor's independence and objectivity and the effectiveness of the audit process;
- guiding and supervising internal audit work and its implementation;
- reviewing the financial information of our Company, including, monitoring the completeness of annual reports and accounts, half-yearly report and quarterly reports, and reviewing significant financial reporting judgments;
- overseeing the financial reporting system, risk management and internal control system, and assessing the effectiveness of internal control;
- coordinating the communication between internal audit department and external audit agency; and
- dealing with other matters that are involved in relevant laws, regulations, rules, normative documents, the Articles of Associations, terms of reference and the listing rules of the place where the Company's shares are [**REDACTED**] or that are authorized by the Board.

Remuneration and Appraisal Committee

We have established a Remuneration and Appraisal Committee with written terms of reference in compliance with Rule 3.25 of the Listing Rules and paragraph E.1 of Part 2 of the Corporate Governance Code. The Remuneration and Appraisal Committee consists of three Directors, namely Dr. Gao Zhengliang, Ms. Xiao Ying and Dr. Jin Huajun. Dr. Gao Zhengliang serves as the chairperson of the Remuneration and Appraisal Committee. The primary duties of the Remuneration and Appraisal Committee include, but not limited to, the following:

- formulating the remuneration plans or packages for Directors and senior management with reference to time contribution and responsibilities, importance and the level of remuneration payable by other related enterprises or comparable companies and conditions of employment for other position held within the Group;
- assessing the remuneration policies and system for all Directors and senior management of the Company, and setting up standardized and transparent procedures to formulate remuneration policies and make recommendations to the Board; monitoring the performance of responsibilities by the Company's Director and senior management and appraising their annual performance;
- determining, with delegated responsibility, the remuneration packages of individual executive Directors and senior management or making recommendations to the Board on the remuneration packages of individual executive Directors and senior management, and such remuneration shall include benefits in kind, pension rights and compensation payments, including any compensation payable for loss or termination of their office or appointment;
- supervising the implementation of the remuneration plan of the Company;
- reviewing and/or approving matters relating to share schemes under Chapter 17 of the Listing Rules; and
- dealing with other matters that involved in relevant laws, regulations, rules, normative documents, the Articles of Associations, terms of reference and the listing rules of the place where the Company's shares are [**REDACTED**] or that are authorized by the Board.

Nomination Committee

We have established a Nomination Committee with written terms of reference in compliance with Rule 3.27A of the Listing Rules and paragraph B.3 of Part 2 of the Corporate Governance Code. The Nomination Committee consists of three Directors, namely Dr. Hui Kai Lung, Ms. Xiao Ying and Dr. Jin Huajun. Dr. Hui Kai Lung serves as the chairperson of the Nomination Committee. The primary duties of the Nomination Committee include, but not limited to, the following:

- reviewing the structure, size and composition (including the skills, knowledge and experience) of the Board at least once every year and making recommendations on any proposed changes to the Board to complement the Company's corporate strategy;
- researching and developing standards and procedures for the election of our Board members and members of the senior management, and making recommendations to our Board;
- conducting extensive search and providing to our Board suitable candidates for Directors and other members of the senior management and making recommendations to the Board on the selection of individuals nominated for Director and senior management;
- examining our Board candidates and members of the senior management and making recommendations to our Board;

- assessing the independence of independent non-executive Directors when identifying and nominating individuals to become independent non-executive directors, demonstrating to the Board whether and why such individuals would be able to devote sufficient time to the Board if he/she will be holding his/her seventh (or more) [**REDACTED**] company directorship; and
- dealing with other matters that involved in relevant laws, regulations, rules, normative documents, the Articles of Associations, terms of reference and the listing rules of the place where the Company's shares are [**REDACTED**] or that are authorized by the Board.

REMUNERATION OF DIRECTORS AND SENIOR MANAGEMENT

During the Track Record Period, our non-executive Directors who did not hold management positions in the Company did not receive remuneration from the Company. Other Directors and senior managers receive their remuneration in the form of salary, annual bonuses, share-based payments and retirement plan.

The total compensation before taxation accrued to our Directors for the years ended December 31, 2024 and 2025 were RMB1.8 million and RMB4.0 million, respectively.

Under the arrangement currently in force, we estimate the total compensation before taxation to be accrued to our Directors for the year ending December 31, 2025 to be approximately RMB3.7 million.

The remuneration paid by our Company to the five highest paid individuals (excluding Directors) for the years ended December 31, 2024 and 2025 were RMB4.8 million and RMB1.6 million, respectively.

We confirmed that during the Track Record Period, no remuneration was paid by our Company to, or receivable by, our Directors or the five highest paid individuals as an inducement to join or upon joining our Company or as compensation for loss of office in connection with the management positions of any subsidiary of our Company.

During the Track Record Period, none of our Directors waived any remuneration. Save as disclosed above, no other payments have been paid, or are payable, by our Company or any of our subsidiaries to our Directors or the five highest paid individuals during the Track Record Period.

CORPORATE GOVERNANCE

Our Company aims to achieve high standards of corporate governance which are crucial to our development and safeguard the interests of our Shareholders. To accomplish this, we expect to comply with the Corporate Governance Code set out in Appendix C1 to the Listing Rules and the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules after the [**REDACTED**].

The roles of chairman of the Board and chief executive officer are currently performed by Dr. Jin. In view of Dr. Jin's substantial contribution to our Group since its establishment and his extensive experience in the industry and corporate management, we consider that having Dr. Jin acting as both our chairman of the Board and chief executive officer will provide strong and consistent leadership to our Group and facilitate the efficient execution of our business strategies. We consider it appropriate and beneficial to our business development and prospects that Dr. Jin continues to act as both our chairman of the Board and chief executive officer after the [**REDACTED**], and therefore currently do not propose to separate the functions of chairman of the Board and chief executive officer of the Company.

While this would constitute a deviation from Code Provision C.2.1 of Part 2 of the Corporate Governance Code, the Board believes that this structure will not impair the balance of power and authority between the Board and the management of our Company, given that: (i) there are sufficient checks and balances in the Board, as a decision to be made by our Board requires approval by at least a majority of our Directors, and our Board comprises three independent non-executive Directors, which is in compliance with the requirement under the Hong Kong Listing Rules; (ii) Dr.

Jin and the other Directors are aware of and undertake to fulfil their fiduciary duties as Directors, which require, among other things, that they act for the benefit and in the best interests of our Company and the Shareholders and will make decisions for our Group accordingly; and (iii) the balance of power and authority is ensured by the operations of the Board which comprises experienced and high calibre individuals who meet regularly to discuss issues affecting the operations of our Company. Moreover, the overall strategic and other key business, financial, and operational policies of our Group are made collectively after thorough discussion at both Board and senior management levels. The Board will continue to review the effectiveness of the corporate governance structure of our Group in order to assess whether separation of the roles of chairman of the Board and chief executive of the Company is necessary.

BOARD DIVERSITY POLICY

We are committed to promoting the culture of diversity in the Company. We have strived to promote diversity to the extent practicable by taking into consideration a number of factors in our corporate governance structure.

We have adopted the board diversity policy (the "**Board Diversity Policy**") which sets out the objective and approach to achieve and maintain diversity of our Board in order to enhance the effectiveness of our Board. Pursuant to the Board Diversity Policy, we seek to achieve Board diversity through the consideration of a number of factors, including but not limited to gender, age, race, cultural background, educational background, industry experience and professional experience. Our Directors have a balanced mix of knowledge and skills, including knowledge and experience in the areas of biopharmaceutical, business administration, compliance, accounting, and financing, etc. Our three independent non-executive Directors have different industry backgrounds, with solid experiences in the fields of finance and securities, representing one-third of the members of our Board. Our Board Diversity Policy is well implemented as evidenced by the fact that there are Directors ranging from [32] years old to 53 years old and comprises four female Directors and five male Directors. Pursuant to the Board Diversity Policy, we aim to maintain at least one female representation in the Board and the current composition of the Board satisfies this target gender ratio. We will implement policies to ensure gender diversity when recruiting staff to develop a pipeline of female senior management and potential successors to the Board. We will strive to enhance our female representation and achieve appropriate balance of gender diversity with reference to the stakeholders' expectation and international and local recommended best practices. Furthermore, we will implement comprehensive programs aimed at identifying and training our female staff who display leadership and potential, with the goal of promoting them to the senior management or the Board.

Our Nomination Committee is responsible for ensuring the diversity of our Board members. After the [**REDACTED**], our Nomination Committee will review the Board Diversity Policy from time to time, develop and review measurable objectives for implementing the policy, and monitor the progress on achieving these measurable objectives to ensure its continued effectiveness. We will disclose in our corporate governance report about the implementation of the Board Diversity Policy on an annual basis.

COMPLIANCE ADVISOR

We have appointed First Shanghai Capital Limited as our compliance advisor (the "**Compliance Advisor**") upon the [**REDACTED**] in compliance with Rule 3A.19 of the Listing Rules. The compliance advisor will provide us with guidance and advice as to compliance with the requirements under the Listing Rules and applicable Hong Kong laws. Pursuant to Rule 3A.23 of the Listing Rules, the compliance advisor will advise our Company, among others, in the following circumstances:

(a) before the publication of any regulatory announcement, circular, or financial report;

(b) where a transaction, which might be a notifiable or connected transaction, is contemplated, including share issues and share repurchases;

(c) where we propose to use the [**REDACTED**] of the [**REDACTED**] in a manner different from that detailed in this Document or where the business activities, development or results of our Group deviate from any forecast, estimate or other information in this Document; and

(d) where the Hong Kong Stock Exchange makes an inquiry to our Company regarding unusual movements in the [**REDACTED**] or [**REDACTED**] of its [**REDACTED**] securities or any other matters in accordance with Rule 13.10 of the Listing Rules.

The term of appointment of the compliance advisor shall commence on the [**REDACTED**] and is expected to end on the date on which we comply with Rule 13.46 of the Listing Rules in respect of our financial results for the first full financial year commencing after the [**REDACTED**] and such appointment may be subject to extension by mutual agreement.